Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909597 · ClinicalTrials.gov registry record · Phase 3
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 756
- Enrollment target
NCT00909597: Completed Phase 3 study, sponsored by Hoffmann-La Roche.
NCT00909597 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 756 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00909597, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 756 participants
- Enrollment target
Study Summary
This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial screening period, patients will be randomized to one of 3 groups, to receive a)taspoglutide 10mg sc weekly, b)taspoglutide 20mg sc weekly after 4 weeks of taspoglutide 10mg sc weekly or c)pioglitazone 45mg/day po after 4 weeks of pioglitazone 30mg/day po.The anticipated time on study treatment is 24 months, and the target sample size is 500+ individuals.
Interventions
- DRUG pioglitazone
- DRUG taspoglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 756 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
What the finished NCT00909597 record still lists
NCT00909597 is an interventional study that assigns participants to a tested intervention. The registered 756 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which pioglitazone is the first listed.
NCT00909597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00909597 about?
NCT00909597 is a clinical study titled "A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes". This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy or sulfonylurea plus metformin combination therapy. After an initial scr...
What is the current status of trial NCT00909597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 756 participants. The study started on 2009-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00909597?
The interventions under investigation include: pioglitazone (DRUG), taspoglutide (DRUG).
Who is sponsoring clinical trial NCT00909597?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00909597's enrollment target sits among peer trials
756 457th of 2000 higher than 1,542 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia